Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Pipeline Developments & Deals by Bioniz Therapeutics

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Therapeutic Area filter
      Study Phase filter
        Country filter
          News Type filter
            Company filter
              refresh

              Companies By Therapeutic Area Full Screen

              Development Status Full Screen

              Bioniz Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Bioniz Announces Positive Efficacy and Safety Data for BNZ-1 from Interim Analysis of Phase 1/2 Study in Cutaneous T-cell Lymphoma

              Contact the Supplier

              Lead Product(s): BNZ-1

              Therapeutic Area: Oncology Product Name: BNZ132-1-40

              Highest Development Status: Phase I/ Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 20, 2020

              Details:

              This study followed a phase 1/2, multi-center, open-label, dose-escalation clinical study of BNZ-1 and was designed to assess its safety and activity as a single systemic agent in rCTCL patients that have failed standard of care and other available treatment options.

              Bioniz Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Almirall eyes $62m takeover of multicytokine specialist Bioniz

              Contact the Supplier

              Lead Product(s): BNZ-1

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Almirall

              Deal Size: $15.0 million Upfront Cash: $15.0 million

              Deal Type: Collaboration January 08, 2020

              Details:

              The deal would expand Almirall's R&D pipeline with an additional three candidates on top of lead drug BNZ-1.

              PharmaCompass__DigitalAd